VRPXVirpax Pharmaceuticals, Inc.

Nasdaq virpaxpharma.com


$ 0.70 $ -0.01 (-1.92 %)    

Wednesday, 22-May-2024 15:03:38 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 0.711
$ 0.70
$ 0.00 x 0
$ 0.00 x 0
$ 0.70 - $ 0.70
$ 0.63 - $ 11.77
48,798
na
832,747
$ 0.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 12-07-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maxim-group-downgrades-virpax-pharmaceuticals-to-hold

Maxim Group analyst Naz Rahman downgrades Virpax Pharmaceuticals (NASDAQ:VRPX) from Buy to Hold.

 virpax-announces-pricing-of-225m-public-offering

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing n...

 virpax-pharmaceuticals-announced-results-for-a-maximum-tolerated-dose-study-in-sprague-dawley-rats-for-probudur

Probudur is Virpax's injectable long-acting liposomal bupivacaine formulation that is injected at the wound site. Probudur ...

 on-april-2-virpax-pharmaceuticals-inc-got-letter-from-nasdaq-stating-that-company-was-not-in-compliance-with-nasdaq-listing-rule

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION